Related topics: multiple myeloma

New class of drugs for the reversible inhibition of proteasomes

As the "recycling plant" of the cell, the proteasome regulates vitally important functions. When it is inhibited, the cell chokes on its own waste. Cancer cells, in particular, are very sensitive because they need the proteasome ...

A new mechanism for reversible proteasome inhibition

In their function as cellular recycling plants, proteasomes fulfill a life-sustaining role in all cells -- including cancer cells. When the proteasomes become inhibited, cells suffocate in their own waste. A reversible proteasome ...

Bortezomib

Bortezomib (INN, originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.

This text uses material from Wikipedia, licensed under CC BY-SA